Rapid determination of gemcitabine and its metabolite in human plasma by LC-MSMS through micro protein precipitation with minimum matrix effect

Journal of Pharmaceutical Sciences and Research

Volumn 1, Issue 3, 2009, Pages 23-32

  Wang, Ling Zhi ^a,b   Yong, Wei Peng ^a   Soo, Ross A ^a   Lee, Soo Chin ^a   Soong, Richie ^b   Lee, How Sung ^c   Goh, Boon Cher ^a,b,c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

2 ; 2 difluorodeoxyuridine; Gemcitabine; Human plasma; LC MSMS

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DEOXYURIDINE DERIVATIVE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

EID: 77953401764     PISSN: None     EISSN: 09751459     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Noble S., Goa K. L., Drugs1997, 54, 447-472.
2. Ramalingam S., Belani C. P., Oncology, 2004, 18, 21-26.
3. Manegold C., Expert Rev Anticancer Ther. 2004, 4, 345-360.
4. Soo R. A., Lim H. L., Wang L. Z., et al., Cancer Chemother Pharmacol. 2003, 52, 153-158.
5. Heinemann V., Xu Y. Z., Chubb S., et al., Cancer Res. 1992, 52, 533-539.
6. Xu Y. Z., Plunkett W., Biochem Pharmacol. 1992, 44, 1819-1827.
7. Venook A. P., Egorin M. J., Rosner G. L., et al., J Clin Oncol. 2000, 18, 2780-2787.
8. Abbruzzese J. L., Grunewald R., Weeks E.A., et al. J Clin Oncol. 1991,9, 491-498.
9. Grunewald R., Kantarjian H., Du M., et al. J Clin Oncol. 1992,10, 406-413.
10. Veerman G., vanHaperen V. W. T. R., Vermorken J. B., et al. Cancer Chemoth Pharmacol. 1996, 38, 335-342.
11. Edzes H. T., Peters G. J., Noordhuis P., et al. Anal Biochem. 1993, 214, 25-30.
12. Guo P. G., Ma J. G., Li S. L., et al. Cancer Chemoth Pharmacol. 2001, 48, 169-76.
13. Venook A. P., Egorin M. J., Rosner G. L., et al. J Clin Oncol. 2000, 18, 2780-2787.
14. Kroep J. R., Giaccone G., Voorn D. A., et al. J Clin Oncol. 1999, 17, 2190-2197.
15. Freeman K. B., Anliker S., Hamilton M., et al. J Chromatogr B. 1995, 665, 171-181.
16. Wang L. Z., Goh B. C., Lee H. S., et al. Ther Drug Monit. 2003,25, 552-557.
17. Lin N. M., Zeng S., Ma S. L., et al. Acta Pharmacol Sin. 2004, 25, 1584-1589.
18. Losa R., Sierra M. I., Guardado C., Fernandez A., et al. Anal Chim Acta. 2005, 528, 255-260.
19. Yilmaz B., Kadioglu Y., Aksoy Y., Anal Biochem. 2004,332, 234-237.
20. Xu Y., Keith B., Grem J. L., J. Chromatography B. 2004, 802, 263-270.
21. Sottani C., Zucchetti M., Zaffaroni M., et al. Rapid Commun Mass Spectrom. 2004, 18, 1017-1023.
22. Guidance for Industry-Bioanalytical Method Validation. Internet at Internet at http://www.fda.gov/cder/guidance/4252fnl.htm
23. Matuszewski B. K., Constanzer M. L., Chavez-Eng C. M., Anal. Chem. 2003, 75, 3029-30.
24. Kostiainen R., Kotiaho T., Kuuranne T., et al. J Mass Spectrom. 2003, 38, 357-372.
25. Karasová G., Kowalska S., Lehotay J., et al. J Sep Sci. 2006, 29, 1074-81.
26. Colin Kellery. Therapeutic Drugs (Second edition) 1998.
27. Chambers E., Wagrowski-Diehl D. M., Lu Z., et al. J. Chromatography B. 2007, 852, 22-34.